Advertisement Pharmaceutical Business review - Page 2907 of 5286 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 14, 2026

BMS secures FDA accelerated approval for Zenbexus in multiple myeloma

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.

Zenbexus is said to be the first CELMoD therapy approved by the FDA for multiple myeloma treatment. Credit: Bristol-Myers Squibb / Business Wire.